

CHANGSHA NATIONAL HIGH-TECH INDUSTRIAL DEVELOPMENT ZONE K沙高新区





湖南长沙高新区生物医药产业北欧招才引智推介会

邀请函

时间: 2017年9月20日(星期三)15:00pm-17:00pm

地点: Karolinska Institutet , MTC, Nobelvägen 16, Solna Campus,

171 77, Stockholm.

背景介绍:

湖南省是近十年 GDP 增长速度最快的省份之一,在两型社会(资源节约型和环境友好型) 的建设策略指引下,注重经济结构和产业布局,在高速发展的同时也积累了丰厚的后发潜 力,成为中国高新技术产业发展的热点。作为湖南省省会的长沙市,在全国33个重点城 市中,2005年至2015年GDP增长了460%,增速领跑全国。长沙高新区则是这个发展背 后的重要的引擎之一。长沙高新区不仅已经成为海外人才创业和就业的优先选择,也是国 际企业寻求发展和合作的首选城市之一,为海外人才提供了广阔的发展机遇。近两年随着 瑞典产业合作平台落地高新区,加快了湖南与北欧的合作,也为北欧的科技人才在湖南长 沙寻求发展机遇带来了便利。

为促进作为长沙产业重点之一的健康产业发展, 高新区带领近十家生物医药领域有着人 才需求的企业,以此次推介会为契机,渴望吸引到优秀的海外人才参与到长沙的发展中。 本次推介会由长沙高新区联合中瑞生命科学协会和北欧可持续发展协会共同组织,期待各 位的积极参与,时不我待,期待同行!

会议议程:

嘉宾签到,自由交谈 14: 50pm

会议开始, 嘉宾介绍 15: 00pm

15: 15pm 主旨演讲,湖南长沙高新区陈志红主任介绍长沙高新区

企业和人才合作推介 16: 00pm

16: 30pm 参会嘉宾自由发言

17: 00pm 会议结束,自由交谈(会议将提供饮料及点心)

代表团参与单位:

长沙高新区管委会

长沙高新区人力资源公共服务中心

长沙高新区管委会重大项目投资局

长沙金域医学检验所有限公司

中信湘雅生殖与遗传专科医院

长沙佰耐特生物科技有限公司

中聚科技股份有限公司

中部生物谷科技有限公司

长沙高新区管委会社会事业局 长沙高新区管委会项目促进处 湖南方盛制药股份有限公司 湖南华瑞达生物科技有限公司 人类干细胞国家工程研究中心 大邦 (湖南) 生物制药有限公司 长沙欧富安科学仪器有限公司

联系人:张寿廷,邮件:<u>shoutingz@hotmail.com</u>,0761619809 为更好地提供服务, 请大家通过邮箱或短信报名。









附件:长沙高新区及企业介绍与人才需求(见下页)

Contents

长沙高新区访问团代表成员	3
长沙国家高新技术产业开发区简介	6
湖南方盛制药股份有限公司	8
大邦(湖南)生物制药有限公司	12
长沙金域医学检验所有限公司	16
湖南华瑞达生物科技有限公司	19
中聚科技股份有限公司	23
长沙欧富安科学仪器有限公司	25
中部生物谷科技有限公司	28
中信湘雅生殖与遗传专科医院有限公司	30
湖南光琇喜新生命科技有限公司	3/









长沙高新区访问团代表成员







姓名	工作单位	职务
Name	Units	Title
陈志红	长沙高新技术产业开发区管理委员会	副主任
Chen Zhihong	Changsha High-tech Industrial Development Zone Administrative Committee	Vice director
宋捷	长沙高新技术产业开发区管理委员会	主任助理
Song Jie	Changsha High-tech Industrial Development Zone Administrative Committee	Assistant director
余龙	长沙高新技术产业开发区管理委员会社会事业局	局长
Yu Long	Social Service Bureau of Changsha High-tech Industrial Development Zone Administrative Committee	Director
胡斌	长沙高新技术产业开发区人力资源公共服务中心	主任
Hu Bin	HR Public Service Center of Changsha High-tech Industrial Development Zone	Director
朱文	长沙高新技术产业开发区管理委员会项目促进办公室	主任
Zhu Wen	Project Promotion Office of Changsha High-tech Industrial Development Zone Administrative Committee	Director
周维	长沙高新技术产业开发区管理委员会重大项目投资局	副局长
Zhou Wei	Major Project Investment Bureau of Changsha High-tech Industrial Development Zone Administrative Committee	Vice Director
周文强	长沙市高层次人才联谊会高新区分会	会长
	湖南方盛制药股份有限公司	首席科学家
Zhou Wenqiang	High-tech Zone Branch Changsha High-level Talents Social Club	Chairman
Wenqiang	Hunan Fangsheng Pharmaceutical Co., Ltd.	Chief Scientist
郭霞凌	大邦 (湖南) 生物制药有限公司	董事长
Guo Xialing	Argus (Hunan) Pharmaceuticals Ltd. (Hunan)	Board Chairman
王洪波	中聚科技股份有限公司	董事长









Wang Hongbo	Jointo Technology Co., Ltd.	Board Chairman
黄庆玺	中部生物谷科技有限公司	董事长
Huang Qingxi	Central Bio-valley Technology Co., Ltd.	Board Chairman
胡亮	中信湘雅生殖与遗传专科医院	研发部主任
Hu Liang	Reproductive & Genetic Hospital of CITIC-Xiangya	Director of R & D Dept.
程腊梅	湖南光琇高新生命科技有限公司	研发部主任
Cheng Lamei	Hunan Guangxiu Life Technology Co., Ltd.	Director of R & D Dept.



CHANGSHA NATIONAL HIGH-TECH INDUSTRIAL DEVELOPMENT ZONE INNOVATORY FEFICIENT REALITIFI II HAPPY







长沙国家高新技术产业开发区简介

Profile of Changsha High-tech Industrial Development Zone

2017年

长沙国家高新技术产业开发区(简称长沙高新区)创建于1988年,是国务院批准建设的首批国家级高新技术产业开发区之一,位于中国中部地区最具竞争力的城市之一、湖南省省会长沙市,规划总面积140平方公里,建成区面积近40平方公里。2016年,长沙高新区"一区四园"实现企业总收入4800亿元,工业总产值突破4000亿元。长沙高新区综合评价排名在全国156个国家级高新区中位居第13位,创新能力进入全国前10位。

Changsha National High-Tech Industrial Development Zone (abbreviated as Changsha High-Tech Zone) was founded in 1988, one of the first national high-tech industrial development zones approved by the State Council, and locates in Changsha, one of the most competitive cities in Central China, the capital city of Hunan Province, with a planned area of 140 sq. km and construction land area of 40 sq. km. In 2016, the enterprises in "One District and Four Parks" of Changsha High-Tech Zone realized a total revenue of RMB 480 billion Yuan with a total industrial product value over RMB 400 billion Yuan. Now Changsha High-Tech Zone ranks 13th among the 156 national high-tech zones in the comprehensive evaluation and among top 10 in innovation ability.

目前,长沙高新区已形成先进装备制造、电子信息及互联网技术应用、新材料、新能源与节能环保、生物医药与健康、现代服务业六大主导产业,先后获批成为国家高技术产业化基地、国家海外高层次人才创新创业基地和国家科技与金融结合示范区。全区注册企业 18487家,其中高新技术企业 612家,占全省 29%;境内外上市企业 40家,占全省 45%;"新三板"挂牌企业 67家,占全省 29%。引进聚集各类创新平台 600多个,其中国家级平台 67个、省级平台 370多个,国家级研发机构数量居全国高新区第 4 位。引进来自美国、德国、日本、意大利、瑞典、香港、台湾等 20余个国家和地区的科技商务机构代表入驻,成功加盟欧洲企业服务网络(EEN)。引进国家"千人计划"专家 16人、湖南省"百人计划"专家 48人,人才数量稳居全省第一,获国务院侨办批准建设全国第九家"侨梦苑"。

Changsha High-Tech Zone has formed six leading industries, including the advanced equipment manufacturing, electronic information and Internet technology application, new materials, new energy and energy conservation and environmental protection, biological medicine and health and









the modern service industry, and has been approved as the National High-Tech Industrial Development Base, the National High Level Overseas Talents Innovation and Entrepreneurship Base and the National Sci-Tech and Finance Combination Demonstration Area. There are 18,487 registered enterprises in the zone, including 612 high-tech enterprises, accounting for 29% of Hunan province; 40 domestic and foreign listed enterprises, accounting for 45% of Hunan province; 67 enterprises got listed in the "New Third Board", accounting for 29% of Hunan province. The zone has introduced more than 600 innovative platforms, including 67 national platforms and over 370 provincial platforms with the number of state-level research and development institutions ranking fourth among the national high-tech zones. The zone has successfully introduced science and technology business organization representatives from more than 20 countries and regions including the United States, Germany, Japan, Italy, Sweden, Hong Kong, Taiwan and etc, and successfully entered into the enterprise service network (EEN) of Europe. The zone has introduced 16 experts under the national "One Thousand Talents Project", 48 experts under the provincial "One Hundred Talents Plan", soundly ranking first in Hunan province. The Overseas Chinese Office under the State Council of China approved the zone to build the ninth "Overseas Chinese Dream Garden".

长沙高新区将深入实施"创新引领、开放崛起"战略,围绕"挺进全国十强、建设世界一 流园区"总目标,着力推进建设国家创新创业引领区,努力打造全国有影响力的科技产业创 新中心。

Changsha High-Tech Zone will further implement the strategy of "Innovation Leading, Openness for Rising", aiming at the overall goal of "Top 10 in China and World Excellent", strive to promote the construction of the national innovation entrepreneurship leading area, to form itself an influential innovation science and technology industry center in China.

Note:







湖南方盛制药股份有限公司

Hunan Fangsheng Pharmaceutical Co., Ltd.

一、公司和参会人员基本信息

I. Basic information of the Company and the conferee

公司简介	湖南方盛制药股份有限公司成立于 2002 年,是一家以化学制剂、原料药、中药提取及中药制剂为主导,集新药研发、生产、销售为一体的集团企业,2014 年在上海证券交易所挂牌上市(股票代码:603998)。方盛制药现辖美国 LipoMedics.Inc、广东暨大基因药物工程中心有限公司、海南博大药业股份有限公司、湖南湘雅制药有限公司等 12 家子公司,员工 1200 余人,建立了覆盖全国 32 个省市的销售网络,2016 年实现销售收入达 53425.68 万元,保持每年 30%以上的高速		
公司地址	湖南省长沙高新区麓谷嘉运路 299 号		
电子邮箱	『箱 │41552748@qq.com │ 联系电话 │		86-731- 88997198
出访人员姓名	周文强	职务	首席科学家

	The Company was established in 2002, and is a business group with		
	chemical agents, crude drugs, Chinese medicine extractions and Chinese		
	medicine preparations as its leading business and integrating the R & D,		
	production and distribution of	new medicine, and v	vas listed in Shanghai
Profile of the	Stock Exchange with a stock co	de of 603998. Now t	he Company holds 12
Company	subsidiaries including US LipoN	nedics.Inc, JNU Guar	ngdong Pharmaceutical
Company	Engineering Research Center fo	or Gene Co., Ltd., Hai	nan Doctor
	Pharmaceutical Co., Ltd. and H	unan Xiangya Medici	ne Co., Ltd., and has
	over 1200 employees, with a sales net covering 32 province-level regions, a		
	yearly revenue of 534.2568 million Yuan in 2016 and a yearly growth over		
	30%.		
Address	No.299, Jiayun Road, Lugu, Changsha High-tech Zone, Hunan Province		
			86-731-
E-mail	41552748@qq.com	Tel	
			88997198
Visitor	Zhou Wenqiang	Title	Chief Scientist







二、项目合作需求

II. Project cooperation demand

项目名称	项目需求	对意向合作 方的要求	合作形式
1类新药			引进或合作

		Requirements	
Project name	Demand	on the other	Cooperation
		party	
One new			Introduction
			or joint
medicine			operation

三、技术合作需求

III. Technical cooperation demand

技术难题	需提供技术支持的 具体内容及要求	对意向合作 方的要求	合作形式
1类新药新剂型			引进或合作







Problem	Contents of and requirements on the technical support needed	Requirements on the other party	Cooperation
New dosage			Introduction
form of one new			or joint
medicine			operation

四、人才引进需求

IV. Demands on HR introduction


岗位	人数	任职要求
新药研发项目经理	3	1、药学、分析专业,能接受在长沙工作; 2、八年以上研发工作经验,其中三年以上项目管理经验; 3、熟悉新药研发工作的内容和工作流程,熟悉药品注册法规和技术指导 原则、熟悉完整的药物研发流程。
小分子生 物分析经 理	1	1、分析化学、药物分析、药代动力学等专业,能接受在长沙工作; 2、在 LC-MS/MS 方法的开发和验证方面有五年以上的实际经验;在样品制备方面有丰富经验,如 LLE,PP 和 SPE 的样品制备。
设备经理	1	1、医学、制药机械、机电一体化等专业,能接受在长沙工作; 2、3年以上冻干制剂肿瘤设备管理工作经验,熟悉肿瘤设备性能与参数,能够安装调试。
临床项目 经理	2	1、医学或药理学专业,熟悉相关法律法规和办公软件使用; 2、具有 4-5 年药品临床监查经验,硕士学历者至少有 1 年临床监查经验。
院长助理	5	医学、药学、管理、财务或金融相关专业。







Post	Num ber	Requirements
Project manager for new medicine R&D	3	 Major in pharmacy or medicine analysis, able to work in Changsha City; Over 8 years experience in R & D, including 3 years of project management; Being familiar with the contents and working flows of new medicine R & D, the medicine registration regulations and technical guidance rules, and the complete medicine R & D procedures.
Small molecule biological analysis manager	1	 Major in analytical chemistry, medicine analysis, pharmacokinetics or any similar, able to work in Changsha City; 5 years experience in LC-MS/MS method development and verification; rich experience in example preparation, such as example preparation of LLE, PP and SPE.
Equipment manager	1	 Major in medicine, pharmaceutical machinery, mechatronics and so on, able to work in Changsha City; 3 years experience of freeze-drying preparation tumor equipment management, familiar with and able to install and debug tumor equipment performances and parameters.
Clinic project manager	2	 Major in medicine or pharmacology, familiar with the related laws and regulations and the usage of office software; 4 to 5 years experience of medicine clinic supervision. Or at least 1 year of such experience for a master.
Assistant president	5	Major in medicine, pharmacy, management, accounting or finance.







大邦 (湖南) 生物制药有限公司

Argus (Hunan) Pharmaceuticals Ltd.

一、公司和参会人员基本信息

I. Basic information of the Company and the conferee

公司简介	大邦(湖南)生物制药有限公司成立于 2007年,注册资本 3772 万元,公司致力于研发、生产和销售高端生物发酵药物产品,包括治疗代谢异常、抗肿瘤、抗病毒和抗真菌类等的中间体和药物,拥有通过 GMP 认证的微生物发酵生物制药平台,具备完整的研发、中试和规模生产的能力。		
公司地址	湖南省长沙高新区林语路 178 号		
电子邮箱	Office@argusph	 联系电话	86-731-
, , ,,,	arms.com	, , <u>-</u> ,	85557699
出访人员姓名	郭霞凌	职务	董事长

	Argus (Hunan) Pharmaceuticals Ltd. was established
	in 2007 with a registered capital of 37.72 million CNY,
	devoted itself to R & D, production and distribution of
Duafile of the	high-end biological fermentation medicines, including
Profile of the	the intermediates and medicines of metabolic
Company	disorder, anti-tumor, antivirus and anti-fungal agents,
	and has microbial fermentation bio-pharmacy
	platform and the complete capability of R & D, pilot
	test and scale production.









Address	No. 178, Linyu Road, Changsha High-tech Zone,		
Address	Hunan Province		
E-mail	Office@argusph	Tel	86-731-
L-IIIdii	arms.com	161	85557699
Visitor	Guo Xialing	Title	Board Chairman

二、项目合作需求

II. Project cooperation demands

项目名称	项目需求	对意向合作方的 要求	合作形式
复方制剂	引进新型制剂产品或 技术,包括奥利司他 的新型制剂。	拥有新型制剂的 开发的技术和能 力	双方商谈确定
新药物	引进基于微生物发酵 的新产品或技术,包 括新药物中间体、原 料药、生物转换酶 等。	拥有新药物中间体、原料药、生物转换酶等产品或技术	双方商谈确定

Project name	Demand	Requirements on the other party	Cooperation
Compound preparation	Introduction of new preparation product or technology, including	Own the development technology and	Decided by negotiation







	new reagent of	capacity of new	
	orlistat.	preparations	
New medicine	Introduction of new preparation product or technology based on microbial fermentation, including intermediate, crude drug, biological transferase and so on.	Own the product or technology of intermediate, crude drug, biological transferase of a new medicine	Decided by negotiation

三、技术合作需求

III. Technical cooperation demand

技术难题	需提供技术支 持的具体内容 及要求	对意向合作方 的要求	合作形式
	适合于工业规		
EPA 的高选择	模生产的高选	拥有成熟的技	技术转移或设
性分离纯化	择性分离纯化	术和设备	备采购
	技术和设备		







Problem	Contents of and requirements on the technical support needed	Requirements on the other party	Cooperation
High-selective separation and purification of EPA	High-selective separation and purification equipments suitable for industrial scale production	Ready technology and equipments	Technical transfer or equipment procurement



长沙金域医学检验所有限公司

Changsha KingMed Diagnosis Co., Ltd.

一、公司和参会人员基本信息

I. Basic information of the Company and the conferee

	於所有限公司创建于 2	2003年,主要开展	
	医学检验、临床试验、	食品卫生检验、司法	法鉴定等业务。公司
, 크셨스	在全国设立了33家实	验室,可为临床与科	研提供 2300 余项
公司简介	检验项目,现为 19000 多家医疗机构提供医学检验外包服		
	务,年检测标本量近4	000 万例,覆盖全国	90%以上人口所在
	的区域,是我国提供检验项目最多最全的医疗机构之一,并已		
	成为领先的临检与病理整体解决方案提供商。		
公司地址	湖南省长沙高新区麓天路 28 号五矿麓谷科技产业园 D2 栋		技产业园 D2 栋
电子邮箱	cskingmed@kingmed.	联系电话	86-731-85839999
=	com.cn		
出访人员姓名	李慧源	职务	总经理

	Changsha KingMed Diagnosis Co., Ltd. was founded in 2003, with
	main business of medical examination, clinic test, sanitary
	inspection of foodstuffs, judicial expertise and so on. The
	company has set up 33 labs with over 2300 kinds of tests for clinic
	and researching purposes, and now renders medical examination
Profile	outsourcing services for over 19000 medical establishments with
	nearly to 40 million test examples annually and covering the
	regions over 90% of the population of China. Now the company is
	one of the medical institutions with the most and most complete
	test items in China, and has become a leading integrated solution
	provider in clinic examination and pathological analysis.









Address	D2 Building, Minmetals Lugu High-tech Industrial Park, No.28,		
Audress	Lutian Road, Changsha I	Changsha High-tech Zone, Hunan Province	
E-mail	cskingmed@kingmed.	Tel	86-731-85839999
Visitor	Visitor Li Huiyuan Title		General Manager

二、项目合作需求

II. Project cooperation demands

项目名称	项目需求	对意向合作方的要 求	合作形式
	寻求已经完成研发的检验新	有完整的研发成果及配套技术体系。	
检验新技术及新 的疾病相关生物	技术或者新的疾病筛查、诊断、监测的生物标记物,合	成果具备转化成产品的成熟技术条	联合生产或 者知识产权
标记物技术研发 转化合作	作在国内进行转化生产,利用金域在全国的市场和网络 迅速进行推广应用。	件;合作方对研发 成果具有独立的知	转让
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	识产权。	

Project name	Demand	Requirements on the other party	Cooperation
New test	Seek for the new test	Own the complete R	
technology, and	technology, of which R & D	& D achievement	Joint
R & D,	have been finished, or the new	and supporting	production or
industrialization	biomarkers for disease	technical system,	intellectual
cooperation of	screening, diagnosis and	with the accessible	property
new biomarkers	monitoring, for	technical conditions	transfer
related to	industrialization in China by	for the	
diseases	cooperation, as well fast	industrialization; has	



# 







promotion and application	an independent and	
through KingMed's distribution	sole intellectual	
net.	property on the	
	achievement.	

# 三、人才引进需求

#### III. Demands on HR introduction

岗位	人数	任职要求
		分子生物学或遗传学博士以上学历, 精通
儿科遗传病及罕见	4	医学检验或分子生物学或分子肿瘤或分子
病中心学科主任	1	遗传或细胞遗传或生物信息等相关知识;具
		备丰富的遗传性疾病相关临床经验。

Post	Number	Requirements
Subject Director of Pediatric Department Genetic Disease and Rare Disease Center	1	Doctor or higher education background in molecular biology or genetics, proficient in medical examination, molecular biology, molecular cancer, molecular genetics, cell heredity or bio-information; rich clinic experience in genetic disease.





# 湖南华瑞达生物科技有限公司

### Hunan Huaruida Bio-tech Co., Ltd.

#### 一、公司和参会人员基本信息

### I. Basic information of the Company and the conferee

公司简介	湖南华瑞达生物科技有限公司成立于 2015 年,是一家立足于生物医药领域的创新型高科技企业,专注于医学检验仪器及体外诊断试剂的研发、生产、销售及服务。公司是湖南省医疗器械行业协会副会长单位,湖南省生物材料学会常务理事单位,已列入《湖南省医疗器械行业"十三五"规划》重点培育企业。公司研制的 800 速全自动生化分析仪HRD800,加样精度高,综合性能稳定,各项测试指标均处于国内领先水平。		
公司地址	湖南省长沙高新区谷苑路 229 号海凭园生产厂房六 1201 室		
电子邮箱	linqiao@hrdbio.com	联系电话	86-731- 88278126/8827 8127
出访人员姓名	邹豪	职务	总经理

Profile	The company was established in 2015, and is an innovative high-tech enterprise based in the field of bio-medicine and devotes itself to the R & D, production, sales and services of medical lab instruments and extracorporal diagnosis agent. The company is a standing member of Hunan Bio-material Society, and has listed as a key enterprise to be promoted in the 13 th 5-Year Plan of Hunan Medical Instruments Industry. HRD 800, a 800 speed fully automatic biochemical analyzer developed by the company, has a high accuracy and stable comprehensive performance and is leading in all test indexes in China.
Address	Room 1201, Workshop 6, Haiping Garden, No.229, Guyuan Road, Changsha High-tech Zone, Hunan Province







			86-731-
E-mail	linqiao@hrdbio.com	Tel	88278126/882781
			27
Visitor	70u H20	Title	General
VISILUI	Visitor Zou Hao		Manager

## 二、项目合作需求

# II. Project cooperation demand

项目名称	项目需求	对意向合作方 的要求	合作形式
生化分析仪的研制	共同开发高端产品,共同 开发关键零部件。	有该方面的产品经 验和市场经验	面议
5 分类血球产品	共同研制或者现有产品商 务合作,共同开发关键零 部件。	有该方面的产品经验和市场经验	面议
医用电解质产品	共同研制或者现有产品商 务合作,电极部件供应。	有该方面的产品经验和市场经验	面议

Project name	Demand	Requirements on the other party	Cooperatio n
R & D of biochemical analyzer	Joint R & D of high-end products and key parts	Production and marketing experience in such field	Negotiable








5-Classification hemocytometer	Joint R & D, or cooperation about current products, joint R & D of key parts  Joint R & D, or cooperation	marketing experience in such field Production and	Negotiable
Medical electrolyte products	about current products, supply of electrode parts	marketing experience in such field	Negotiable

## 三、技术合作需求

# III. Technical cooperation demands

技术难题	需提供技术支持的具体	对意向合作方	合作形式
N/II/II/C	内容及要求	的要求	
生化体外诊断	生产工艺与质量控制	长期合作	面议
试剂	一工 二乙 一次 里红 啊		ши
5 分类血球试剂	生产工艺与质量控制	长期合作	面议
电解质试剂	生产工艺与质量控制	长期合作	面议

Problem	Contents of and requirements on the technical support needed	Requirements on the other party	Cooperati on
Bio-chemical vitro diagnosis reagent	Production technology & quality control	Long-term cooperation	Negotiabl e









5-classification	Due de estica de de esta esta en	l a a a tama	No setield
hematological	Production technology	Long-term	Negotiabl
	& quality control	cooperation	е
reagent			
Electrolyte	Production technology	Long-term	Negotiabl
reagent	& quality control	cooperation	е



# 中聚科技股份有限公司

### Jointo Technology Co., Ltd.

### 公司和参会人员基本信息表

### Basic information of the company and confereee

	The company was established in 2014 with a registered capital
	of 50 million Yuan, and is a high-tech medical equipment
	enterprise integrating R & D, production and distribution. The
Duefile	company's main products include thulium doped fiber laser
Profile	surgical instrument, medical laser fiber, flexible fiber opic
	endoscope, fully digital sonicator, wireless Doppler fetus-voice
	meter, ureter nephroscope conduit, compression nebulizer,
	tooth punching machine, sphygmomanometer and so on.







	Floor 6, Building 6, Xincheng High-tech Park, No. 588,		
Address	Yuelu Road West, Changsha High-tech Zone, Hunan		
	Province		
Email	zjkjgf6666@163.	Tel	86-731-
Linaii	com	TCI	82883960
Visitor	Wang Hongbo	Title	Board Chairman



# 长沙欧富安科学仪器有限公司

## Changsha Oufuan Scientific Instruments Co., Ltd.

#### 一、公司和参会人员基本信息表

### I. Basic information of the Company and the conferee

出访人员姓名	李大庆	职务	总经理
电子邮箱	tonyldq@163.com	联系电话	85585005
上 7 上 从		四万山江	86-731-
公司地址	湖南省长沙高新区麓龙路 199 号麓谷坐标 A 栋 908		
	抢救。		
公司简介	端医疗器械,广泛应用于各级医用手术麻醉及急诊		
	界首次实现同时等	输氧、可视、气管	插管于一体的高
	售,公司开发的	医用可视气管管理	医疗器械, 是业
	年,专注于高端	医疗电子产品的研	发、生产和销
	长沙欧富安	科学仪器有限公司	成立于 2013

	The company was established in 2013 and devotes
	itself to the R & D, production and distribution of
	high-end medical electronic products. The medical
	visible trachea management instrument development
Profile	by the company is a high-end medical instrument first
	integrating oxygen therapy, visibility and trachea
	cannula at a same time in the field, and is widely used
	in all grades of medical operative anesthesia and
	salvages.








Address	Room 908, Building A, Lugu Coordinate, No. 199, Lulong Road, Changsha High-tech Zone, Hunan Province		
Email	tonyldq@163.com	Tel	86-731- 85585005
Visitor	Li daqing	Title	General Manager

## 二、项目合作需求

# II. Project cooperation demand

项目名称	项目需求	对意向合作方的 要求	合作形式
高端医疗器械技术引进	产品技术或专利	需具有国际领先 技术,并有自己 的知识产权,有 意转让或合作生	购买专利或 技术,或合 作生产。

Project name	Demand	Requirements on the other party	Cooperation
Technical		Technology	Procurement
introduction of	Product	leading in the	of patent or
high-end	technology of	world and with	technology,
medical	patent	independent	or joint
instruments		intellectual	production







	property, willing	
	to transfer or joint	
	produce product	



# 中部生物谷科技有限公司

Central Bio-valley Technology Co., Ltd.

# 公司和参会人员基本信息

Basic information of the Company and the conferee

公司简介	中部生物谷科技有企业,专注于投资创新临床医疗服务模式企业创新科技型企业 11 家,亿元,旗下有实业、金块,已在洛杉矶和特拉出访,公司主要希望考益公司和项目公司。	以及医疗大健康产业 资本市场总市值(信 融服务和国际创投平 维夫设立美国总部和	领域的应用、创新 ,现控股中国医疗 站值)规模超过 20 台三个核心业务板 以色列总部。本次
公司地址	湖南省长沙市芙蓉区芙蓉中路 2 段 111 号华菱大厦 21 楼		
电子邮箱	Tracy.cbv@qq.com	联系电话	86-731- 82416666
出访人员姓名	黄庆玺	职务	董事长

	The company is a medical high-end investment & operation
	platform enterprise, and devotes itself to the investment of the
	innovative biological technical application in medical instrument
	field, innovative clinic service model enterprises and big medical
Profile of the	health industry. Now the company holds 11 Chinese medical
Company	innovative high-tech enterprises, with a total value (estimated) in
Jones Jones	capital market over 2 billion Yuan, covering 3 core business blocks
	of industry, financing service and international venture capital
	investment platform, and has set up US headquarters and Israel
	headquarters respectively in Los Angeles and Tel Aviv. This visit of
	the company is to inspect the platform companies and project









	companies in the big hea medical instruments.	lth industry and of me	dical treatment and
Address	Floor 21, Valin Building, N	No.111, Furong Middle	Road Section 2,
	Furong District, Changsha	a City, Hunan Province	
F	T	T-1	86-731-
E-mail	Tracy.cbv@qq.com	Tel	82416666
Visitor	Huang Qingxi	Title	Board Chairman





# 中信湘雅生殖与遗传专科医院有限公司

# Reproductive & Genetic Hospital of CITIC-Xiangya

## 一、公司和参会人员基本信息

## I. Basic information of the Company and the conferee

	中信湘雅生殖与遗传专科医院创建于 2002 年,是中国首家		
	现代化大型生殖与遗传专科医院,辅助生殖技术处国际领先水		
	平,目前已建立的单基因病植入前遗传学诊断(PGD)技术平台		
小司符合	有 125 种,能够完成	单基因病基因检测种类	已达到 180 余种。
公司简介	2016 年,医院门诊量	28 万人次,"试管婴儿	L"治疗超过 4.08 万个
	周期,同比增长 15.6%,平均妊娠率在 60%以上。医院遗传中心		
	是国内最大的细胞和分子遗传学诊断中心之一,2016 年为 1.56		
	万余名患者提供遗传咨询服务。		
公司地址	湖南省长沙市湘雅路 86 号		
	zxxykyb@163.co		86-731-82355100
电子邮箱	m m	联系电话	转 <b>8973</b>
	111		17 03/3
出访人员姓名	胡亮	职务	科研部主任

	The hospital was established in 2002, and is the first Chinese modern
	reproductive & genetic specialized hospital with leading assisted
	reproduction technology in the world. Now the hospital has set up 125
	kinds of monogenic disease pre-implantation genetic diagnosis (PGD)
	technical platforms and is able to detect over 180 kinds of monogenic
Profile	genes. In 2016 the hospital accepted 280,000 clinical visits, and
	completed over 40,800 periods of test tube baby treatments, up
	15.6%, with an average rate of pregnancy over 60%. The heredity
	center of the hospital is one of the largest domestic cell and molecular
	genetics diagnosis centers, and in 2016 rendered heredity consultation
	services for over 15,600 patients.







Address	No.86, Xiangya Road, Changsha City, Hunan Province		
	zxxykyb@163.co		86-731-
Email	, , -	Tel	82355100to
	m		extension 8973
Visitor	Hu Liang	Title	Director of R & D
			Dept.


## 二、项目合作需求

## II. Project cooperation demand

项目名称	项目需求	对意向合作方 的要求	合作形式
早期胚胎发育	合作研究早期胚胎 发育的机制	有实力的研究 机构或者团队	科研合作

Project name	Demand	Requirements on the other party	Cooperati
	Jointly research the	Competent	Researchi
Early embryonic	mechanism of early	researching	ng
development	embryonic	institute or	cooperati
	development	team	on

## 三、技术合作需求



# CHANGSHA NATIONAL HIGH-TECH INDUSTRIAL DEVELOPMENT ZONE | 长沙高新区





### III. Technical cooperation demands

技术难题	需提供技术支 持的具体内容 及要求	对意向合作方 的要求	合作形式
生物 3D 打印	利用 3D 打印技 术制作微器官	有技术积累和 基础	科研合作
高效分离优质 精子	微流控	有相关技术基础	研发合作

Problem	Contents of and requirements on the technical support needed	Requirements on the other party	Cooperation
3D bio-printing	Making micro- organ by 3D printing	With technical accumulation and background	Researching cooperation
Effective separation of high-quality sperm	Micro-fluidics	With the background of the related technologies	R & D cooperation

### 四、人才引进需求

IV. Demands on HR introduction







岗位	人数	任职要求	
项目负责人	不限	有研究基础和合适的项目可以 进行转化 合作形式不限	
坝日贝页八	个限	进行转化,合作形式不同	

Post	Number	Requirements	
		Having researching background	
Project leader	Unlimited	and project suitable to be	
		industrialized, without limitation	
		to forms of cooperation	

# CHANGSHA NATIONAL HIGH-TECH INDUSTRIAL DEVELOPMENT ZONE | 长沙高新区







## 湖南光琇高新生命科技有限公司

Hunan Guangxiu Life Technology Co., Ltd.

### 一、 公司和参会人员基本信息

### I. Basic information of the Company and the conferee

公司地址	病的再生医学新疗法新技术和肿瘤的综合	対解、糖尿病、急性所法以及人造血液产品, 会防治疗新技术的临所 会防治疗新技术的临所 大沙高新区麓谷麓云 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、	以及基因诊断的 末应用。
公司简介	湖南光琇高新生命科技有限公司成立于 2005 年,注册资本 1.936 亿元,承担了国内唯一的"人类干细胞国家工程研究中心"的实体运营,构建了世界首个人类体细胞克隆囊胚,建立了国内第一株人类胚胎干细胞系,现已建立具有自主知识产权的世界最大的胚胎干细胞库,开发了人类干		







	The company was established in 2005 with a registered capital			
	of 193.6 million Yuan, which assumes the physical operation of			
	the sole Human Stem Cell National Engineering Researching			
	Center in China, and has formed the first human somatic cell			
	cloning blastaea in the world, built up the first human			
	embryonic stem cell	line in China, and has	built up the largest	
Profile	embryonic stem cell	bank in the world and	with the	
Profile	independent intellec	tual property, develop	oed human stem cell	
	product line, developed the new regenerative medical			
	treatment and man-made blood for the refractory diseases			
	including cerebral palsy, diabetes and acute hepatic failure, as			
	well the clinic applications of the new genetic diagnosis			
	technology and the new comprehensive cancer prevention and			
	treatment technology.			
Address	No. 8, Luyun Road, Lugu, Changsha High-tech Zone, Hunan			
Address	Province			
E-mail	None	Tel	86-731-88395675	
L-IIIall	None	iei	00-/31-003330/3	
Visitor	Cheng Lamei	Title	Director of R &	
			D Dept.	

# 二、项目合作需求

## II. Project cooperation demand

项目名称	项目需求	对意向合作方 的要求	合作形式
应用干细胞治疗难	细胞产品、药物标准化和	具备细胞产品或者	项目合作
治性疾病的产品或	规模化生产硬件和运行经	药物开发、生产的	
药物开发	验	能力	
临床应用型干细胞	了解欧洲临床应用型干细	具备干细胞开发和	项目合作
开发	胞的相关规定和要求	生产能力	







Project name	Demand	Requirements on the other party	Cooperatio n
The product or medicine development for treating the refractory disease by the application of stem cells	Hardware and operation experience about cell products, medicine standardization and scale production	Development and production capacity of cell products or medicine	Project cooperation
Clinic and applicable stem cell development	Understanding the related regulations and requirements of the clinic applicable stem cell in Europe	Development and production capacity of stem cell	Project cooperation

# 三、技术合作需求

## III. Technical cooperation demand


技术难题	需提供技术支持的 具体内容及要求	对意向合作方 的要求	合作形式
3D 生物打印技 术	(1) 提供针对肝脏、胰腺、心脏等组织或者器官所需要的生物材料、细胞和生长因子的各种最佳组合;(2) 合理选择 3D 生物打印平台;(3) 通过3D 生物打印出有血管系统的组织器官,并且能融合于人体整个血液循环系统。	具备 3D 生物打印 技术的平台,成 功地实施过生物 组织或器官打印 的案例,并有意 提供技术和产品 输出服务	引进或者共同开发
基因编辑技术	(1) 该技术能够高效、 精确的实施定点基因导 入、敲出;(2)实现低 脱靶率或零脱靶率; (3)在干细胞以及人胚	具备运用特定基 因编辑技术实施 定点基因导入、 敲出的成功案例	引进或者共同开发





	胎等材料上实现精准的基 因编辑。	以及该技术应用 的知识产权授权	
微流控技术	(1) 微流控芯片技术扩增特定的 DNA 片段; (2) 基于微流控芯片的细胞分类、检测技术; (3) 通过微流控系统开发单细胞分选技术。	具备微流控设备 开发能力和专业 人才,拥有微流 控技术在细胞检 测、分选等生物 医疗领域应用的 案例。	引进或者共同开发

		T	T
Problem	Contents of and requirements on the technical support needed	Requirements on the other party	Cooperation
3D bio-printing technology	(1) Provision of all kinds of best portfolios of the biomaterial, cell and growth factor needed by the tissue or organs including liver, pancreas and heart; (2) reasonable selection of 3D bio-printing platform; (3) by 3D bio-printing, to produce the tissue and organs with blood vascular system, compatible with the whole human blood circulation system.	Owns the platform with 3D bioprinting technology, and successful cases of printing of biotissue or organs, and willing to offer technical service or product transfer	Introduction or joint development
Gene editing technology	(1) The technology is able to efficiently and accurately realize gene introduction and knockout; (2) low or zero off-target rate; (3) accurate gene editing realized in stem cell and human embryo and other materials.	Owns the successful cases of fixed point gene introduction and knockout by the special gene editing technology, and the intellectual property about the technical application.	Introduction or joint development
Micro-fluidic technology	(1) Micro-fluidic chip technology to enlarge the special DNA fragment; (2) cell classification and	Development capacity and professional talents of micro-	Introduction or joint development







detecting technologies	fluidic	
based on micro-fluidic chip;	equipments, and	
(3) development of	cases of the cell	
unicellular separation	detecting and	
technology by micro-fluidic	separation by	
system	micro-fluidic	
	technology in bio-	
	medicine field	

## 四、人才引进需求表

#### IV. Demands on HR introduction

岗位	人数	任职要求
3D 生物打印技术专家	1人	博士及以上学历,熟悉 3D 生物组织和器官打印方面的技术并从事相关研究工作。
干细胞定向诱导分 化技术专家	1-2 人	博士及以上学历,熟悉多能干细胞向功能细胞(优先神经、心肌、胰岛方向)诱导分化技术并从事相关研究工作。
基因编辑技术专家	1人	博士及以上学历,熟悉哺乳动物基因编辑技术并从事相关研究工作。
微流控应用技术专 家	1人	博士及以上学历,熟悉哺乳动物细胞微流控分选技术并从事相关研究工作。
生物信息学分析技 术专家	1人	博士及以上学历,熟悉基因组、转录组、表观遗传学组、蛋白组等大数据分析并从事相关研究工作。

Post	Number	Requirements
3D bio-printing expert	1	Doctor or higher education background, familiar with 3D biological tissue and organ printing technology and engaging in the related research.
Stem induced directional differentiation expert	1-2	Doctor or higher education background, familiar with the technology of stem cell induced directional differentiation into function cell (nerve, myocardium and pancreas islet is preferential) and engaging in the related research.
Gene editing expert	1	Doctor or higher education background, familiar with mammal gene editing and engaging in the related research.
Micro-fluidic application expert	1	Doctor or higher education background, familiar with mammal cell micro-fluidic separation and engaging in the related research.







Bio-information analysis expert		Doctor or higher education background, familiar with the big data analysis of genome, transcriptome, epigenetic group and proteome and engaging in the related research.
---------------------------------	--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------